Merck, Codexis renew enzyme production pact; J&J recalls a lot of Imodium; Ranbaxy relaunches skin product;

> Six years in and Merck ($MRK) likes so much its partnership with Codexis ($CDXS), which has been developing enzymes for Merck's manufacturing processes, that the two have signed another three-year deal. Release

> Ranbaxy Laboratories is re-launching its skincare drug Sotret, which was pulled from the market when the FDA banned 30 drugs that were tied to two plants in India, but this time around it will be manufactured by its partner in the project, Cipher Pharmaceuticals. Story

> Baxter International ($BAX) facilities in Halle and Bielefeld in Germany have received certification for safe handling of compounds. Item

> Johnson & Johnson's ($JNJ) McNeil Consumer Healthcare, which has gotten accustomed to recalling products in large quantities, is retrieving a lot of Imodium, nearly 54,000 packages. Story

> AlpVision and Nolato Medical are working together on a new packaging that can use an iPhone to protect against counterfeiting. Item

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies and senior-level discussions from leaders who are innovating the way we look at the intersection of digital technologies and marketing in Europe.